News & Events

Latest news & events at NeRRe Therapeutics.

NeRRe Therapeutics appoints Dr Steve Pawsey as Chief Medical Officer

NeRRe Therapeutics, is pleased to announce the appointment of Dr Steve Pawsey as Chief Medical Officer. Dr Pawsey, an anaesthetist by training, has extensive experience in the global pharmaceutical and biotechnology sector, having worked in clinical development roles for over 20 years. He will lead the progress of NeRRe’s two lead NK receptor antagonists, orvepitant and NT-814, towards late-stage clinical development, for which activity an oversubscribed £23m fundraising was recently announced.

Read More

NeRRe Therapeutics raises £23 million in oversubscribed Series B financing round

New investors Fountain Healthcare Partners, Forbion Capital Partners and OrbiMed join existing investors Advent Life Sciences and Novo A/S

Stevenage, UK, 5th January 2017 – NeRRe Therapeutics (‘NeRRe’), a clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common, chronic and debilitating conditions caused by neuronal hypersensitivity, announced it has raised £23 million in an oversubscribed Series B financing round.

The funds will be used by NeRRe to generate Phase 2 data on orvepitant, its lead oral NK-1 antagonist candidate as a potential new treatment for a common, chronic respiratory condition; and to advance NT-814, a dual NK-1,3 antagonist, into Phase 2 trials as a potential non-hormonal treatment of distressing post-menopausal vasomotor symptoms.

The financing round involved a syndicate of leading transatlantic life sciences investors led by new investor Fountain Healthcare Partners, and co-led by Forbion Capital Partners and OrbiMed. Existing investors, Advent Life Sciences and Novo A/S also participated.

Read More

Dr Mary Kerr to join NeRRe Therapeutics as CEO

Stevenage, UK, 23 September 2015.

NeRRe Therapeutics Ltd, a clinical stage company developing a portfolio of neurokinin (NK) receptor antagonists, is pleased to announce that Dr Mary Kerr1 is joining the company as CEO at the beginning of October. Mary has spent the majority of her career on the R&D/commercial interface in global strategy and regional operational roles at the pharmaceutical company GSK and predecessor companies, predominantly in the speciality and orphan drug areas. She has also been appointed an Operating Partner at Advent Life Sciences, one of NeRRe’s investors.

Read More

New Drug Discovery Company NeRRe Therapeutics Created to Develop Neurokinin Antagonists from GSK

London, UK, 19th December 2012.

NeRRe Therapeutics Ltd, is launched today to develop a portfolio of clinical and pre-clinical neurokinin receptor antagonists divested from GlaxoSmithKline (“GSK”).

NeRRe has raised £11.5 million ($18.4 million) in Series A financing to support the progression of these molecules into clinical studies in diseases for which there is substantial unmet medical need.

Read More